• Explore /
  • Poster
  • / Alpelisib and fulvestrant efficacy in HR-positive HER2-negative <i>PIK3CA</i>-mutant advanced breast cancer: Data from the French early access program.

Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program.

Abstract Video & Slides Poster

Authors

null

Diana Bello

Institut Curie, Saint-Cloud, France

Diana Bello , Alexandre Bertucci , Thibault De La Motte Rouge , Cyriac Blonz , Sarra Akla , Julien Grenier , Caroline Bailleux , Marc Antoine Benderra , Helene Simon , Isabelle Desmoulins , Zoé Tharin , Emmanuelle Renaud , Suzette Delaloge , Marion Bertho , Paul H. Cottu , Anthony Goncalves , François-Clément Bidard , Florence Lerebours

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 1064)

DOI

10.1200/JCO.2021.39.15_suppl.1064

Abstract #

1064

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Sara A. Hurvitz

First Author: Peter Cornelius

First Author: Dejan Juric

First Author: Timothy A. Yap